Caixin
Sep 13, 2024 05:04 PM
CHINA

In Depth: Why Hong Kongers Are Flocking to the Mainland for Health Care

00:00
00:00/00:00
Listen to this article 1x
Two Hong Kong seniors ask about using elderly health care vouchers at the cross-border medical information desk at the University of Hong Kong-Shenzhen Hospital. Photo: Wen Simin/Caixin
Two Hong Kong seniors ask about using elderly health care vouchers at the cross-border medical information desk at the University of Hong Kong-Shenzhen Hospital. Photo: Wen Simin/Caixin

Hong Kong residents have long traveled north into Guangdong province for relatively cheaper luxuries like dining out, spa treatments and shopping. But increasingly moving up the list of reasons is health care, as more and more Hong Kongers seek out medical treatment on the Chinese mainland.

But Hong Kong boasts some of the best medical standards globally, and its residents have enjoyed the highest average life expectancy worldwide for seven consecutive years — 80.7 years for men and 86.8 years for women.

loadingImg
You've accessed an article available only to subscribers
VIEW OPTIONS

Download our app to receive breaking news alerts and read the news on the go.

Get our weekly free Must-Read newsletter.

Share this article
Open WeChat and scan the QR code
DIGEST HUB
Digest Hub Back
Explore the story in 30 seconds
  • Increasingly, Hong Kong residents seek medical care in Shenzhen for affordable non-emergency procedures, accessible prices, and swift services.
  • Luminal motivations include cost-effective dental care, routine surgeries, and traditional Chinese medicine, with costs significantly lower than in Hong Kong.
  • Despite the trend, only a small fraction of Hong Kong residents cross the border for medical services, while the majority still rely on local healthcare systems.
AI generated, for reference only
Explore the story in 3 minutes

Hong Kongers have increasingly traveled to Guangdong province, specifically Shenzhen, for medical care, adding to a list of reasons that traditionally included cheaper luxuries like dining and shopping [para. 1]. Despite Hong Kong's high medical standards and world-leading life expectancy rates (80.7 years for men and 86.8 years for women) [para. 2], residents are opting for medical services on the mainland [para. 3].

Shenzhen has seen a surge in cross-border medical tourism from Hong Kong, with local hospitals like HKU-SZH reporting significant outpatient visits for non-emergency services such as cosmetic procedures, dentistry, ophthalmology, and traditional Chinese medicine. For instance, HKU-SZH recorded 40,493 outpatient visits from Hong Kong residents in the first quarter of this year [para. 4][para. 5][para. 6]. Dr. Yu Sze Yuen from HKU-SZH notes that many Hong Kong patients come for general practice services that handle chronic conditions like diabetes and hypertension [para. 7].

The affordability and quick service on the mainland are major draws. For example, Wang Yuan, a 70-year-old Hong Konger, reported substantial savings on reading glasses and dental services in Shenzhen compared to Hong Kong [para. 8][para. 9][para. 10]. Routine surgeries also tend to be cheaper; knee replacement surgery costs around HK$27,000 in Shenzhen compared to over HK$100,000 in a private Hong Kong hospital [para. 11]. Moreover, traditional Chinese medicine, much sought after by Hong Kong residents, is available at much lower costs on the mainland [para. 12].

Even for severe medical conditions like cancer, the mainland offers more affordable innovative treatments. Drugs like Pfizer's Lorlatinib for lung cancer have seen significant price reductions due to government negotiations, making them more accessible to patients [para. 13][para. 14][para. 15]. However, the bulk of Hong Kong's population still seeks local medical treatment, with only a tiny fraction crossing the border for care [para. 16][para. 17].

Hong Kong's dual-track health care system combines a public safety net with a private sector for premium, expedited services. The public system is under strain due to high demand and staff shortages; specialist consultations often have a minimum waiting period of 10 weeks [para. 20][para. 21][para. 22]. As the aging population increases pressure on the system, more residents are finding the mainland's medical services an appealing alternative [para. 23].

The Hong Kong government is also encouraging cross-border medical care. The Elderly Health Care Voucher (EHCV) Greater Bay Area Pilot Scheme now allows residents aged 65 and older to use their vouchers in designated hospitals and clinics on the mainland, facilitating over 160,000 visits since 2015 [para. 24][para. 25].

To combat the high costs in Hong Kong, many residents are exploring mainland medical insurance options. These include employee basic and urban-rural resident basic medical insurance plans, with flexible employment categories accessible with a mainland residence card [para. 26][para. 27]. For example, Lin Yi, a Hong Konger, has maintained his mainland insurance even after relocating back to Hong Kong, taking advantage of favorable reimbursement rates [para. 28][para. 29][para. 30].

This trend of utilizing mainland medical services reflects a cost-effective and faster alternative for many Hong Kong residents, driven by both individual initiative and government policy encouragement [para. 18][para. 19][para. 31].

AI generated, for reference only
Who’s Who
Pfizer Inc.
Pfizer Inc. developed Lorlatinib, the world’s first third-generation ALK inhibitor approved in mainland China for treating advanced or metastatic non-small cell lung cancer with anaplastic lymphoma kinase positivity. Initially priced at 40,500 yuan per box, its price was significantly reduced to 15,804 yuan per box in 2023 after being included in the national insurance list.
AI generated, for reference only
What Happened When
Since 2015:
Nearly 16,000 people have utilized the EHCV scheme at the HKU-SZH, facilitating over 160,000 visits, with total expenditure exceeding HK$50 million.
2020:
There were 20.76 million outpatient visits in Hong Kong’s public health care system, accounting for 30% of the total outpatient services.
By 2022:
Lin Yi shifted his mainland insurance payment category from 'working in the mainland' to 'flexible employment' after resigning and returning to Hong Kong.
April 2022:
Lorlatinib was approved on the mainland for treating locally advanced or metastatic non-small cell lung cancer with anaplastic lymphoma kinase positivity.
As of 2023:
Lorlatinib was included in the national insurance list, leading to a significant price reduction to 15,804 yuan per box.
On Feb. 19, 2024:
The Hong Kong Health Bureau announced an expansion of the Elderly Health Care Voucher (EHCV) Greater Bay Area Pilot Scheme.
AI generated, for reference only
Subscribe to unlock Digest Hub
SUBSCRIBE NOW
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin Biz Roundup: Indonesia Woos Chinese Investment in Solar, EV Battery Production
00:00
00:00/00:00